Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study

Respiratory Medicine

Volumn 102, Issue 11, 2008, Pages 1511-1520

  Vogelmeier, Claus ^a   Kardos, Peter ^b   Harari, Sergio ^c   Gans, Steven J M ^d   Stenglein, Stephan ^e   Thirlwell, Jackie ^f  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Respiratory and Sleep Medicine   (Germany)

^c San Giuseppe Hospital   (Italy)

^d ST JANSDAL HOSPITAL   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Clinical study; Formoterol; Tiotropium

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHOULDER PAIN; SIDE EFFECT; TREMOR;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TREATMENT OUTCOME;

EID: 55749112997     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.07.020     Document Type: Article

References (32)

1. Chapman K.R., Mannino D.M., Soriano J.B., Vermeire P.A., Buist A.S., Thun M.J., et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27 (2006) 188-207
2. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2007). http://goldcopd.com Updated (based on an April 1998 NHLBI/WHO Workshop) At:
3. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
4. Dahl R., Greefhorst L.A., Nowak D., Nonikov V., Byrne A.M., Thomson M.H., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
5. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper Jr. J.A., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
6. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., and Cornelissen P.J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 55 (2000) 289-294
7. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 17 (2004) 35-39
8. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
9. Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., and Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 100 (2006) 1925-1932
10. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26 (2005) 214-222
11. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129 (2006) 509-517
12. Rabe K.F., Timmer W., Sagkriotis A., and Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Chest 134 (2008) 255-262
13. Tashkin D.P., Littner M., Andrews C.P., Tomlinson L., Rinehart M., and Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 102 (2008) 479-487
14. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2001 (based on an April 1998 NHLBI/WHO Workshop). At: http://goldcopd.com.
15. Dahl R., Creemers J.P., Van Noord J., Sips A., Della Cioppa G., Thomson M., et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 71 (2004) 126-133
16. Jones P.W., Quirk F.H., Baveystock C.M., and Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992) 1321-1327
17. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
18. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
19. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD 2 (2005) 111-124
20. Puhan M.A., Mador M.J., Held U., Goldstein R., Guyatt G.H., and Schünemann H.J. Interpretation of treatment changes in six-minute walk distance in patients with COPD. Eur Respir J (2008) Jun 11 [Epub ahead of print]
21. Wise R.A., and Brown C.D. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. J COPD 2 (2005) 125-129
22. Haalboom J.R., Deenstra M., and Struyvenberg A. Hypokalaemia induced by inhalation of fenoterol. Lancet 1 8438 (1985) 1125-1127
23. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol 110 6 Suppl. (2002) S322-S328
24. Hay J.G., Stone P., Carter J., Church S., Eyre-Brook A., Pearson M.G., et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5 (1992) 659-664
25. Molimard M., Bourcereau J., Le Gros V., and Bourdeix I. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Respir Med 99 (2005) 695-702
26. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 (2003) 659-664
27. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 (2007) 545-555
28. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81 Erratum: Eur Respir J 2003;21:912
29. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31 (2008) 416-469
30. Suissa S., Ernst P., Vandemheen K.L., and Aaron S.D. Methodological issues in therapeutic trials of chronic obstructive pulmonary disease. Eur Respir J 31 (2008) 927-933
31. Campbell S.C., Criner G.J., Levine B.E., Simon S.J., Smith J.S., Orevillo C.J., et al. Cardiac safety of formoterol 12 μg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 20 (2007) 571-579
32. Morganroth J., Golisch W., and Kesten S. Electrocardiographic monitoring in COPD patients receiving tiotropium. COPD 1 (2004) 181-190